Eli Lilly Soared by 39% in 2025, but Here’s Another Healthcare Stock to Buy in 2026
Eli Lilly’s (NYSE: LLY) share price jumped 39% in 2025, driven by investors eager to benefit from the…
Novo Nordisk shares plunge on outlook warning as Mounjaro rival races ahead
Weight loss drug maker Novo Nordisk has seen shares slump after warning over a sales plunge amid price…
My Top AI Healthcare Stock to Buy and Hold for 20 Years
Eli Lilly has made several moves to boost its artificial intelligence (AI) capacity. It could help complement its…
How Will Ozempic and Wegovy Sales Aid NVO’s Upcoming Q4 Results?
Novo Nordisk NVO is a dominant player in the cardiometabolic space, mainly due to the encouraging uptake of its…
Eli Lilly Soared by 39% in 2025, but Here’s Another Healthcare Stock to Buy in 2026
Eli Lilly (NYSE: LLY) delivered a gain worthy of a technology growth stock last year. The pharma giant’s…
Novo’s Wegovy pill hits 18,410 US prescriptions in encouraging debut week
By Sriparna Roy Jan 23 (Reuters) – Novo Nordisk’s Wegovy pill was prescribed 18,410 times in the U.S.…
Takeaways on turmoil surrounding FDA fast-track drug program
WASHINGTON (AP) — A plan to slash drug review times at the Food and Drug Administration is sparking…
This Company Is Doubling Down on AI. Is the Stock a Buy?
Investors looking to capitalize on the growing artificial intelligence (AI) industry are mostly turning to the tech sector,…
FDA commissioner’s drug review plan sparks alarm
WASHINGTON (AP) — The Food and Drug Administration commissioner’s effort to drastically shorten the review of drugs favored…
From OpenAI’s offices to a deal with Eli Lilly — how Chai Discovery became one of the flashiest names in AI drug development
Drug discovery, the art of identifying new molecules to develop pharmaceuticals, is a notoriously time-consuming and difficult process.…
Eli Lilly’s Most Promising Weight Loss Drug May Come With a Surprising Benefit: Pain Relief
Retatrutide’s recent trial results suggest it may be even better than Eli Lilly’s already approved GLP-1 medication, tirzepatide.…
How Will Mounjaro and Zepbound Sales Aid LLY’s Upcoming Q4 Results?
Eli Lilly LLY has emerged as a dominant force in the cardiometabolic market, driven by strong demand for its…